Substance / Medication

Deferoxamine mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Prevalence of bone destruction in patients with TALAROMYCES MARNEFFEI infection: A systematic review and meta-analysis.
Zhou Junhong, Xi Deshuang, Teng Yilin et al. · Int J Infect Dis · 2025
PMID: 39667554Meta-Analysis
Validation of quantitative [F]NaF PET uptake parameters in bone diseases: a systematic review.
de Ruiter Ruben D, Zwama Jolien, Raijmakers Pieter G H M et al. · Ann Nucl Med · 2025
PMID: 39729191Meta-AnalysisFull text (PMC)
Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.
Zamoner Soraya Mayumi Sasaoka, Takase Henrique Mochida, Riyuzo Marcia Camegaçava et al. · Int Urol Nephrol · 2024
PMID: 37964112Meta-AnalysisFull text (PMC)
Skeletal indicators of pathology in the context of early tooth loss in children: A systematic literature review.
Ribeiro Ana, Decaup Pierre-Hadrien, Andriantavy Marion et al. · Int J Paleopathol · 2024
PMID: 39029336Meta-Analysis
The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.
Yu Yao, Zhao Wei, Zhu Chunpeng et al. · PLoS One · 2015
PMID: 25875777RCTFull text (PMC)
Effects of Deferoxamine Mesylate on Hematoma and Perihematoma Edema after Traumatic Intracerebral Hemorrhage.
Yu Jian, Yuan Qiang, Sun Yi-Rui et al. · J Neurotrauma · 2017
PMID: 28462672Trial
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.
Selim Magdy, Yeatts Sharon, Goldstein Joshua N et al. · Stroke · 2011
PMID: 21868742TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Deferoxamine mesilate (substance)
SNOMED CT
387224002
UMLS CUI
C0011148

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.